0
0
A recent study published in The Lancet has found that fewer than 20% of women in low- and middle-income countries (LMICs) are diagnosed with breast or cervical cancer at an early stage, compared to about 40% of women in high-income nations. The research underscores profound global disparities in cancer detection, access to care, and survival outcomes among women worldwide.
The Study and Its Scope
The VENUSCANCER study—led by the Cancer Survival Group at the London School of Hygiene and Tropical Medicine (LSHTM)—analyzed data from over 275,000 women across 39 countries who were diagnosed with breast, cervical, or ovarian cancer between 2015 and 2018. According to lead researcher Professor Claudia Allemani, this database represents “the largest and most detailed global population-based dataset” for these cancer types.
The study’s findings reveal a consistent trend: women in poorer nations are being diagnosed much later, often when their disease is already advanced. Late detection substantially lowers their chances of survival and limits treatment options—a disparity that persists even when accounting for advancements in medical technology and screening methods available globally.
Key Findings
-
Diagnosis rates: Less than 20% of women in LMICs were diagnosed at early stages, compared to roughly 40% in wealthier countries.
-
Ovarian cancer: Globally, ovarian cancer remains the most challenging to detect early—fewer than one in five cases are diagnosed before metastasis.
-
Treatment disparities: While early-stage patients generally received surgery in most countries, adherence to international treatment guidelines varied widely.
-
Age factor: Older women were less likely to receive guideline-aligned treatment compared to younger patients, highlighting potential systemic biases based on age.
-
Metastatic cases: Metastatic breast cancer accounted for under 10% of diagnoses in high-income nations but between 2% and 44% in LMICs.
Professor Allemani emphasized the vital role of population-based cancer registries in tracking treatment consistency and outcomes, calling for stable financial support from governments as part of national cancer control plans.
Expert Perspectives
Dr. Ritu Bhatia, oncologist at the All India Institute of Medical Sciences (AIIMS), New Delhi, who was not involved in the study, said the findings “mirror what Indian practitioners observe daily.”
“Many women come to tertiary cancer centers when their cancer has already reached stage three or four. The reasons are multifold—lack of screening programs, stigma, poor access to diagnostic services, and limited awareness,” she explained.
Dr. Farhana Yusuf, a global health policy expert affiliated with WHO’s Eastern Mediterranean Regional Office, added that the study “provides evidence to strengthen WHO’s Global Breast Cancer Initiative and Cervical Cancer Elimination Initiative, which aim to cut preventable deaths through early screening and improved access to care.”
Why Late Diagnosis Persists
Several social, structural, and economic factors contribute to the disparities identified in the VENUSCANCER study:
-
Limited health infrastructure: Many LMICs lack structured screening programs for breast and cervical cancers.
-
Economic barriers: Low-income women may delay seeking care because of treatment costs or travel distances.
-
Cultural stigma: In countries where women’s health topics remain taboo, breast and gynecological symptoms often go unreported.
-
Training gaps: Health workers may miss early signs due to inadequate training in recognizing subtle cancer symptoms.
Global Health Context
The study’s authors stress that reducing mortality from women’s cancers requires stronger cancer registries and sustainable investment in screening, diagnosis, and treatment systems.
According to the World Health Organization (WHO), breast cancer is now the world’s most commonly diagnosed cancer, accounting for 12% of all new cancer cases globally. Cervical cancer, though highly preventable through vaccination and screening, continues to claim over 300,000 women’s lives annually, with 90% of deaths occurring in LMICs.
Implementing cost-effective interventions—such as HPV vaccination, mammography screening, and public education campaigns—could dramatically change the outlook. For example, WHO’s Cervical Cancer Elimination Initiative aims to vaccinate 90% of girls by age 15, screen 70% of women by age 35 and 45, and ensure treatment for 90% of identified precancers.
Implications for Public Health
Addressing the disparities highlighted in the VENUSCANCER study will require both political commitment and community engagement. Experts argue that integrating early detection programs into existing maternal and primary healthcare systems could be one of the most cost-effective strategies.
Dr. Bhatia noted that “even small steps, such as community-based breast awareness workshops or mobile HPV screening units, can have exponential impacts when properly scaled.”
Governments must also build centralized cancer registries, ensuring high-quality data collection on patient demographics, diagnosis stages, and treatment outcomes—key elements for equitable cancer control.
Limitations and Future Directions
The researchers acknowledged limitations, including incomplete data in some regions and potential differences in registry methodologies. Yet, their findings emphasize the urgent need to bridge diagnostic inequities through global partnerships and increased funding for women’s health research.
While universal access to early detection remains distant for many LMICs, investments in national cancer control programs—coupled with education and awareness—could help reverse the trend.
Conclusion
The VENUSCANCER study sheds light on a critical truth: where a woman lives continues to heavily determine whether she survives cancer. Building equitable systems for screening, diagnosis, and treatment is not simply a scientific necessity but a moral imperative for global health.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
“Study shows less than 20 pc of women in low and middle-income countries diagnosed with cancer at early stage.” The Economic Times Health, October 2025 .https://health.economictimes.indiatimes.com/news/industry/study-shows-less-than-20-pc-of-women-in-low-and-middle-income-countries-diagnosed-with-cancer-at-early-stage/124751101?utm_source=top_story&utm_medium=homepage
